Literature DB >> 20079390

An oral delivery system for indomethicin engineered from cationic lipid emulsions and silica nanoparticles.

Spomenka Simovic1, He Hui, Yunmei Song, Andrew K Davey, Thomas Rades, Clive A Prestidge.   

Abstract

We report on a porous silica-lipid hybrid microcapsule (SLH) oral delivery system for indomethacin fabricated from Pickering emulsion templates, where the drug forms an electrostatic complex with cationic lipid present in the oil phase. Dry SLH microcapsules prepared either by spray drying (approximately 1-5 microm) or phase coacervation (20-50 microm) exhibit a specific internal porous matrix structure with pore diameters in the range of 20 to 100 nm. Dissolution studies under sink conditions and in the presence of electrolytes revealed a decreased extent of dissolution; this confirms the lipophilic nature the drug-lipid complex and its location in the oil phase. Orally dosed in-vivo studies in rats showed complete drug absorption and statistically higher fasted state bioavailability (F) (p<0.05) in comparison to aqueous suspensions and o/w submicron emulsions of indomethacin. It is postulated that the SLH microcapsules improve oral absorption via complete solubilisation of drug-lipid electrostatic complexes during enzymatic lipolysis in the GI track. 2010. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20079390     DOI: 10.1016/j.jconrel.2010.01.008

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  9 in total

Review 1.  Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance.

Authors:  Angel Tan; Shasha Rao; Clive A Prestidge
Journal:  Pharm Res       Date:  2013-06-18       Impact factor: 4.200

2.  Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.

Authors:  Angel Tan; Andrew K Davey; Clive A Prestidge
Journal:  Pharm Res       Date:  2011-05-11       Impact factor: 4.200

3.  First in man bioavailability and tolerability studies of a silica-lipid hybrid (Lipoceramic) formulation: a Phase I study with ibuprofen.

Authors:  Angel Tan; Nasrin Ghouchi Eskandar; Shasha Rao; Clive A Prestidge
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

4.  A magnetic nanoparticle stabilized gas containing emulsion for multimodal imaging and triggered drug release.

Authors:  Wei Guo; Diancheng Li; Jia-an Zhu; Xiaohui Wei; Weiwei Men; Dazhi Yin; Mingxia Fan; Yuhong Xu
Journal:  Pharm Res       Date:  2014-04-10       Impact factor: 4.200

Review 5.  Membrane mimetic surface functionalization of nanoparticles: methods and applications.

Authors:  Jacob Weingart; Pratima Vabbilisetty; Xue-Long Sun
Journal:  Adv Colloid Interface Sci       Date:  2013-05-02       Impact factor: 12.984

6.  Porous Silica-Supported Solid Lipid Particles for Enhanced Solubilization of Poorly Soluble Drugs.

Authors:  Rokhsana Yasmin; Shasha Rao; Kristen E Bremmell; Clive A Prestidge
Journal:  AAPS J       Date:  2016-04-05       Impact factor: 4.009

7.  A Novel Functional Emulsifier Prepared with Modified Cassava Amylose with Octenyl Succinic Anhydride and Quercetin: Preparation and Application in the Pickering Emulsion.

Authors:  Hailing Zhang; Haiming Chen; Shan Jiang; Xiaoning Kang
Journal:  Molecules       Date:  2021-11-15       Impact factor: 4.411

8.  Curcumin encapsulation in Pickering emulsions co-stabilized by starch nanoparticles and chitin nanofibers.

Authors:  Yeong-Sheng Lee; Rodrigo Tarté; Nuria C Acevedo
Journal:  RSC Adv       Date:  2021-05-05       Impact factor: 4.036

9.  Silica-Lipid Hybrid Microparticles as Efficient Vehicles 
for Enhanced Stability and Bioaccessibility of Curcumin.

Authors:  Yudi Ma; Qiang Wang; Dantong Wang; Juan Huang; Rui Sun; Xinyu Mao; Yuan Tian; Qiang Xia
Journal:  Food Technol Biotechnol       Date:  2019-09       Impact factor: 3.918

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.